Deep knowledge on 
 small-molecule drugs and 
 the 110,000 global patents 
 covering them 

Free Patent Expiration Alerts


Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Milnacipran hydrochloride - Generic Drug Details

« Back to Dashboard
Milnacipran hydrochloride is the generic ingredient in two branded drugs marketed by Cypress Bioscience, Liberty Pharma Inc, and Amneal Pharms, and is included in three NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

This ingredient has forty-one patent family members in twenty-five countries.

There are nineteen drug master file entries for milnacipran hydrochloride. Eight suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: milnacipran hydrochloride

Tradenames:2
Patents:4
Applicants:3
NDAs:3
Drug Master File Entries: see list19
Suppliers / Packaging: see list8

Pharmacology for Ingredient: milnacipran hydrochloride

Tentative approvals for MILNACIPRAN HYDROCHLORIDE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET;ORAL12.5MG
<disabled><disabled>TABLET;ORAL25MG
<disabled><disabled>TABLET;ORAL50MG

Clinical Trials for: milnacipran hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms
MILNACIPRAN HYDROCHLORIDE
milnacipran hydrochloride
TABLET;ORAL205081-001Apr 22, 2016RXNo<disabled><disabled>
Cypress Bioscience
SAVELLA
milnacipran hydrochloride
TABLET;ORAL022256-001Jan 14, 2009RXNo7,994,220<disabled> <disabled>
Cypress Bioscience
SAVELLA
milnacipran hydrochloride
TABLET;ORAL022256-003Jan 14, 2009RXYes6,602,911<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: milnacipran hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,915,246Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain<disabled in preview>
6,635,675 Method of treating chronic fatigue syndrome<disabled in preview>
7,820,643Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: milnacipran hydrochloride

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2004009069<disabled in preview>
South Africa200803469<disabled in preview>
European Patent Office1928446<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Connect with Social Media:

`abc